View in EDS

Comparison of Pyrrolobenzodiazepine Dimer Bis-imine versus Mono-imine: DNA Interstrand Cross-linking, Cytotoxicity, Antibody-Drug Conjugate Efficacy and Toxicity.

Saved in:
Bibliographic Details
Title: Comparison of Pyrrolobenzodiazepine Dimer Bis-imine versus Mono-imine: DNA Interstrand Cross-linking, Cytotoxicity, Antibody-Drug Conjugate Efficacy and Toxicity.
Authors: Tiberghien AC; Tumor Targeted Delivery, Oncology R&D, AstraZeneca, London, United Kingdom., Vijayakrishnan B; Tumor Targeted Delivery, Oncology R&D, AstraZeneca, London, United Kingdom., Esfandiari A; Cancer Research UK, Drug DNA Interactions Research Group, UCL Cancer Institute, London, United Kingdom., Ahmed M; Tumor Targeted Delivery, Oncology R&D, AstraZeneca, London, United Kingdom., Pardo R; Tumor Targeted Delivery, Oncology R&D, AstraZeneca, London, United Kingdom., Bingham J; Cancer Research UK, Drug DNA Interactions Research Group, UCL Cancer Institute, London, United Kingdom., Adams L; Tumor Targeted Delivery, Oncology R&D, AstraZeneca, London, United Kingdom., Santos K; Tumor Targeted Delivery, Oncology R&D, AstraZeneca, London, United Kingdom., Kang GD; Tumor Targeted Delivery, Oncology R&D, AstraZeneca, London, United Kingdom., Pugh KM; Tumor Targeted Delivery, Oncology R&D, AstraZeneca, London, United Kingdom., Afif-Rider S; Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland., Vashisht K; Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland., Haque K; Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland., Tammali R; Tumor Targeted Delivery, Oncology R&D, AstraZeneca, Gaithersburg, Maryland., Rosfjord E; Tumor Targeted Delivery, Oncology R&D, AstraZeneca, Gaithersburg, Maryland., Savoca A; Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland.; Drug Metabolism and Pharmacokinetics, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Hartley JA; Cancer Research UK, Drug DNA Interactions Research Group, UCL Cancer Institute, London, United Kingdom., Howard PW; Tumor Targeted Delivery, Oncology R&D, AstraZeneca, London, United Kingdom.
Source: Molecular cancer therapeutics [Mol Cancer Ther] 2023 Feb 01; Vol. 22 (2), pp. 254-263.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 36722141
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Comparison of Pyrrolobenzodiazepine Dimer Bis-imine versus Mono-imine: DNA Interstrand Cross-linking, Cytotoxicity, Antibody-Drug Conjugate Efficacy and Toxicity.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Tiberghien+AC%22">Tiberghien AC</searchLink>; Tumor Targeted Delivery, Oncology R&D, AstraZeneca, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Vijayakrishnan+B%22">Vijayakrishnan B</searchLink>; Tumor Targeted Delivery, Oncology R&D, AstraZeneca, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Esfandiari+A%22">Esfandiari A</searchLink>; Cancer Research UK, Drug DNA Interactions Research Group, UCL Cancer Institute, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Ahmed+M%22">Ahmed M</searchLink>; Tumor Targeted Delivery, Oncology R&D, AstraZeneca, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Pardo+R%22">Pardo R</searchLink>; Tumor Targeted Delivery, Oncology R&D, AstraZeneca, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Bingham+J%22">Bingham J</searchLink>; Cancer Research UK, Drug DNA Interactions Research Group, UCL Cancer Institute, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Adams+L%22">Adams L</searchLink>; Tumor Targeted Delivery, Oncology R&D, AstraZeneca, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Santos+K%22">Santos K</searchLink>; Tumor Targeted Delivery, Oncology R&D, AstraZeneca, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Kang+GD%22">Kang GD</searchLink>; Tumor Targeted Delivery, Oncology R&D, AstraZeneca, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Pugh+KM%22">Pugh KM</searchLink>; Tumor Targeted Delivery, Oncology R&D, AstraZeneca, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Afif-Rider+S%22">Afif-Rider S</searchLink>; Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland.<br /><searchLink fieldCode="AU" term="%22Vashisht+K%22">Vashisht K</searchLink>; Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland.<br /><searchLink fieldCode="AU" term="%22Haque+K%22">Haque K</searchLink>; Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland.<br /><searchLink fieldCode="AU" term="%22Tammali+R%22">Tammali R</searchLink>; Tumor Targeted Delivery, Oncology R&D, AstraZeneca, Gaithersburg, Maryland.<br /><searchLink fieldCode="AU" term="%22Rosfjord+E%22">Rosfjord E</searchLink>; Tumor Targeted Delivery, Oncology R&D, AstraZeneca, Gaithersburg, Maryland.<br /><searchLink fieldCode="AU" term="%22Savoca+A%22">Savoca A</searchLink>; Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland.; Drug Metabolism and Pharmacokinetics, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Hartley+JA%22">Hartley JA</searchLink>; Cancer Research UK, Drug DNA Interactions Research Group, UCL Cancer Institute, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Howard+PW%22">Howard PW</searchLink>; Tumor Targeted Delivery, Oncology R&D, AstraZeneca, London, United Kingdom.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101132535%22">Molecular cancer therapeutics</searchLink> [Mol Cancer Ther] 2023 Feb 01; Vol. 22 (2), pp. 254-263.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Association+for+Cancer+Research%2C+Inc%22">American Association for Cancer Research, Inc </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101132535 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1538-8514 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215357163%22">15357163 </searchLink><i>NLM ISO Abbreviation: </i>Mol Cancer Ther <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36722141
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1158/1535-7163.MCT-21-0693
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 254
    Titles:
      – TitleFull: Comparison of Pyrrolobenzodiazepine Dimer Bis-imine versus Mono-imine: DNA Interstrand Cross-linking, Cytotoxicity, Antibody-Drug Conjugate Efficacy and Toxicity.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Tiberghien AC
      – PersonEntity:
          Name:
            NameFull: Vijayakrishnan B
      – PersonEntity:
          Name:
            NameFull: Esfandiari A
      – PersonEntity:
          Name:
            NameFull: Ahmed M
      – PersonEntity:
          Name:
            NameFull: Pardo R
      – PersonEntity:
          Name:
            NameFull: Bingham J
      – PersonEntity:
          Name:
            NameFull: Adams L
      – PersonEntity:
          Name:
            NameFull: Santos K
      – PersonEntity:
          Name:
            NameFull: Kang GD
      – PersonEntity:
          Name:
            NameFull: Pugh KM
      – PersonEntity:
          Name:
            NameFull: Afif-Rider S
      – PersonEntity:
          Name:
            NameFull: Vashisht K
      – PersonEntity:
          Name:
            NameFull: Haque K
      – PersonEntity:
          Name:
            NameFull: Tammali R
      – PersonEntity:
          Name:
            NameFull: Rosfjord E
      – PersonEntity:
          Name:
            NameFull: Savoca A
      – PersonEntity:
          Name:
            NameFull: Hartley JA
      – PersonEntity:
          Name:
            NameFull: Howard PW
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 02
              Text: 2023 Feb 01
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 1538-8514
          Numbering:
            – Type: volume
              Value: 22
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: Molecular cancer therapeutics
              Type: main
ResultId 1